Anti-viral therapy for chronic hepatitis B and cirrhosis: monotherapy or combination?

At present,the response rate of anti- viral therapy for chronic hepatitis B still needs to be increased. Therefore,combination therapy including nucleosides combined with nucleotides,as well as interferon combined with nucleosides and nucleotides,is being explored by many researchers. According to recent studies,monotherapy using potent nucleosides or nucleotides is the first choice for initial treatment of chronic hepatitis B,and tenofovir is an alternative choice for nucleosides- and nucleotides- resistant patients. Combination therapy using nucleosides and nucleotides is recommended for patients with high viral load and positive HBe Ag. Entecavir combined with tenofovir can be used for patients with a treatment history and even for those with multiple drug resistance. The long- term therapy with interferon can be used to achieve HBe Ag and HBs Ag seroconversion in patients already treated with nucleosides and nucleotides.